Clomid is a prescription fertility medicine for women with irregular or absent ovulation and selected men under specialist supervision. Its active ingredient, clomifene citrate, stimulates the hormonal signals that support follicular development and ovulation.
Clomid is a prescription fertility medicine containing clomifene citrate for ovulation induction in women who do not ovulate regularly. It may also be used under specialist supervision for selected male endocrine disorders. Clomifene blocks estrogen feedback in the brain, increasing follicle-stimulating hormone and luteinizing hormone release.
The dose is stated on the pack — follow the leaflet. Clomid tablets contain clomifene citrate, a selective estrogen receptor modulator, or SERM.
The dose is stated on the pack — follow the leaflet. The exact starting day depends on the menstrual pattern and the fertility protocol. Some protocols begin around cycle day 2, 3, 4, or 5, while people with irregular cycles may receive a different plan after bleeding or pregnancy has been excluded.
A typical clinical pathway includes:
If ovulation does not occur, a prescriber may increase the dose in a later cycle. Dose escalation should not happen within the same cycle unless a fertility specialist has given explicit instructions.
If a dose is missed, the correct action depends on how late the dose is and where the patient is in the prescribed course. Taking an extra tablet is not a routine substitute. The prescriber or fertility clinic should give the specific missed-dose instruction.
A transvaginal ultrasound can show follicle development and help identify excessive ovarian response. A progesterone blood test later in the cycle can help confirm ovulation. The FDA prescribing information describes the need to limit repeated treatment cycles and to assess the response before continuing therapy [2].
The medicine acts mainly at estrogen receptors in the hypothalamus and pituitary gland. By reducing the brain’s perception of circulating estrogen, clomifene encourages the pituitary gland to release more follicle-stimulating hormone (FSH) and luteinizing hormone (LH).
This hormonal response supports follicular development in the ovaries and may trigger ovulation. Clomid does not create an egg and cannot correct every cause of infertility. Its benefit depends on the presence of ovarian function and an appropriate hormonal response.
The pharmacological sequence is:
FSH stimulates the growth of ovarian follicles, which are small structures containing developing eggs. As a follicle matures, it produces more estrogen. LH contributes to final follicular maturation and the release of the egg.
Clomid is mainly used for ovulation induction in women with ovulatory dysfunction. Common clinical contexts include irregular or absent ovulation associated with polycystic ovary syndrome (PCOS), although treatment selection depends on the person’s medical history and fertility assessment.
A fertility evaluation normally considers:
Clomid may be considered when the ovaries can respond to stimulation and pregnancy is medically appropriate. It is not a general treatment for unexplained menstrual irregularity.
Male use is usually off-label and belongs to specialist endocrinology or fertility practice. Clomifene may raise endogenous LH and FSH, which can support testosterone production and sperm formation in selected men with secondary hypogonadism. It is not suitable for every man with low testosterone, and laboratory testing is needed before and during treatment.
The World Health Organization describes infertility as a condition requiring assessment of both partners. Treating ovulation alone cannot overcome severe male-factor infertility, blocked fallopian tubes, or major uterine abnormalities [1].
The preferred fertility treatment depends on the cause of infertility, PCOS status, previous response, ovarian reserve, sperm findings, and local clinical practice. Treatment selection may change after ultrasound or laboratory results. Monitoring requirements differ between oral and injectable treatments. The underlying cause remains central to treatment selection. Follow-up helps clinicians assess benefit and risk.
| Approach | Main role |
|---|---|
| Clomifene citrate | Oral ovulation induction through increased FSH and LH signalling |
| Letrozole | Aromatase inhibition; often considered for ovulation induction in PCOS |
| Gonadotropins | Injectable FSH or combined gonadotropin stimulation with ultrasound monitoring |
| IVF | Fertilisation outside the body after ovarian stimulation and egg collection |
Letrozole is an oral aromatase inhibitor that temporarily lowers estrogen production. This can increase pituitary FSH release. International fertility guidance frequently considers letrozole for anovulatory PCOS, while the choice still depends on the patient’s history and the prescriber’s protocol.
Injectable gonadotropins directly provide hormones that stimulate follicular development. They can be useful when oral induction has not worked, although they require closer ultrasound monitoring and carry a greater risk of excessive ovarian response.
A human chorionic gonadotropin trigger may be used in selected protocols to imitate the LH surge. IVF may be considered when tubal disease, severe sperm abnormalities, endometriosis, reduced ovarian reserve, or unsuccessful ovulation induction changes the treatment plan.
Metformin may be used for selected people with PCOS, especially when insulin resistance is present. It is not a direct replacement for Clomid and does not induce ovulation through the same mechanism.
The European Medicines Agency explains that treatment selection must balance expected benefit with risks such as ovarian overstimulation and multiple pregnancy [3].
Clomid should not be used in the presence of:
Clomid is not suitable for every person seeking pregnancy. The prescribing clinician usually confirms the cause of ovulatory dysfunction and evaluates pregnancy safety before starting a medicated cycle.
Clomid should not be continued after pregnancy is confirmed. It is also not appropriate if you have unexplained bleeding, an ovarian cyst that has not been assessed, uncontrolled thyroid, adrenal, or pituitary disease, or visual symptoms from previous clomifene treatment.
A pregnancy test may be required before a cycle begins.
Clomid is often tolerated without severe complications, but its estrogen-receptor activity can produce noticeable hormonal effects. Reported adverse effects include:
Visual symptoms deserve more attention than ordinary headache or hot flushes. Spots, flashes, blurred vision, double vision, or difficulty seeing in low light can become persistent in rare cases. Further treatment requires clinical review.
Ovarian enlargement may cause pelvic pressure or discomfort. Severe abdominal swelling, rapid weight gain, breathlessness, vomiting, reduced urination, or intense pelvic pain can indicate ovarian hyperstimulation syndrome (OHSS) or another urgent complication.
Clomid can also increase the chance of multiple pregnancy, especially twins. Multiple gestation carries higher risks for premature birth, pregnancy-related hypertension, and other complications. The risk is one reason fertility treatment may involve ultrasound monitoring.
Clomifene can cause ovarian cyst enlargement, especially when cysts are present before treatment. It should not be used when an ovarian cyst has not been assessed.
Seek urgent assessment for severe pelvic pain, fainting, marked abdominal swelling, breathing difficulty, sudden visual loss, or heavy bleeding.
Several practical errors can reduce the usefulness of a Clomid cycle:
One easy mistake is treating Clomid as a general hormone-balancing tablet. Its effect is cyclical and depends on ovarian responsiveness. Another is assuming that a regular bleed automatically proves that ovulation occurred; hormone testing can provide more useful confirmation.
In clinical practice, doctors usually explain that Clomid improves the probability of ovulation; it does not guarantee conception. A successful response requires a viable egg, functioning fallopian tubes, adequate sperm, and suitable timing.
Prescribers also pay attention to the cumulative number of treatment cycles. Repeated exposure without a documented response adds inconvenience and side effects without solving the underlying problem. A change in strategy may be more useful than simply increasing the dose.
SAHPRA provides the South African regulatory framework for medicines, while fertility clinicians apply product information alongside patient-specific assessment. The National Institute for Health and Care Excellence recommends structured investigation and treatment planning rather than repeated unsupervised ovulation-induction cycles [4].
Ovulation commonly occurs several days after the five-day tablet course, though the timing varies between cycles. Ultrasound or a progesterone blood test can provide stronger evidence than symptoms alone. The FDA product information from 2012 describes cycle-based treatment rather than continuous daily use [5].
Clomid cannot open blocked fallopian tubes. It may stimulate ovulation, but an egg and sperm still need a functioning route for fertilisation. Tubal assessment is therefore relevant before repeated ovulation-induction cycles, as reflected in World Health Organization guidance from 2023.
Some specialists prescribe clomifene off-label for selected men with secondary hypogonadism or fertility-related low testosterone. It may increase the body’s own LH and FSH production, which can support testosterone and sperm production in appropriate cases. Treatment requires hormone testing and follow-up; it is not a universal treatment for male infertility. WHO fertility guidance from 2023 supports assessment of both partners rather than treating one person without investigating the other.
Clomid increases the likelihood of multiple ovulation compared with an untreated cycle. Twin pregnancy is more common than higher-order multiple pregnancy, but the exact risk depends on age, ovarian reserve, dose, and individual response. Monitoring helps the clinician identify an excessive follicular response during treatment; the FDA label from 2012 describes the need for clinical supervision.
Blurred vision, flashing lights, spots, or reduced visual clarity require prompt medical assessment. Further tablets should not be taken until the prescriber has reviewed the symptom. Persistent visual disturbance is a recognised safety concern in clomifene prescribing information; the FDA label from 2012 advises clinical review before further treatment.
Clomid may be used for ovulation induction in selected people with PCOS, especially when irregular or absent ovulation is the main fertility problem. Letrozole is also widely considered for anovulatory PCOS, so the preferred option depends on treatment history and clinical factors. SAHPRA-regulated prescribing should follow an individual assessment rather than a fixed online dosing plan, consistent with NICE fertility guidance from 2021.
Clomid may help release an egg, but pregnancy also depends on sperm quality, tubal function, uterine factors, egg quality, and timing. Some people ovulate without conceiving, while others do not respond adequately to the medicine. A lack of pregnancy after an appropriate monitored course should prompt review of the wider fertility assessment, not automatic dose escalation; NICE guidance from 2021 supports structured reassessment.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I had irregular periods linked with PCOS. The five-day course was simple, but I needed ultrasound monitoring because the first scan showed more than one developing follicle. I had mild hot flushes and a headache, which settled after the course.
The first month did not result in ovulation, so the fertility doctor changed the plan for the next cycle. The tablets were easy to take, although the uncertainty around timing was stressful.
I noticed flashing lights while reading at night. I stopped taking further tablets and contacted the clinic. The symptom was taken seriously, and I was not advised to restart until I had been assessed.
Clomifene was prescribed after blood tests showed low testosterone with low-normal gonadotropins. My follow-up included repeat hormone tests rather than relying only on how I felt.
